Biotech IP valuation
Consultancies and data platforms that value biotechnology and pharmaceutical patent portfolios for licensing negotiations, M&A, litigation and capital raises — translating a patent estate covering therapeutics, diagnostics or platform technologies into a defensible monetary figure.
1 · What it gives
Biotech IP valuation is a B2B services category in which specialist consultancies and data platforms assign a defensible monetary value to a biotechnology or pharmaceutical company’s patent portfolio, supporting licensing negotiations, M&A due diligence, litigation damages and capital raises. Ocean Tomo runs engagement-based valuations for biotechnology startups, including a documented capital-raise engagement for a company holding IP covering cancer and rare-disease therapeutics and diagnostics. Consor IP Consulting applies AI-assisted methods to patent valuation, treating patents as strategic business assets rather than purely legal instruments. Charles River Associates (CRA) brings economic-valuation expertise to life-sciences disputes, including cases where the product being valued may never reach market — a distinctly biotech valuation problem. EverEdge Global, headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios. GreyB provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — built for IP counsel and licensing teams assessing monetization readiness, including standard-essential-patent (SEP) readiness reporting. Inngot, a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets for smaller biotech and life-sciences companies.
The key directions of biotech IP valuation are:
- Engagement-based patent-portfolio valuation: custom valuations for a specific transaction — licensing negotiation, M&A, or a capital raise — grounded in the patent estate’s claims, remaining life and competitive position.
- AI-assisted valuation methodology: applying machine-learning and data-driven models to patent valuation, moving beyond purely qualitative expert judgment.
- Litigation and damages valuation: economic analysis supporting patent-infringement and licensing disputes, including cases involving products that have not yet reached market approval.
- Portfolio analytics and monetization readiness: structured analysis of prosecution history, litigation exposure, claims and citations to assess which patents in a portfolio are genuinely ready for licensing or sale.
Sectoral value chain#
[Patent portfolio identification] ──> [Prior-art & claims analysis] ──> [Valuation methodology selection]
│
(Royalty-rate benchmarking)
│
[Negotiation/litigation support] <──── [Valuation report delivery] <─── [Monetary value determination]
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Portfolio identification | Cataloguing the patents, applications and other intangible assets that make up the biotech company’s IP estate. | In: Patent filings, R&D records. Out: IP asset inventory. |
| Prior-art and claims analysis | Assessing patent strength, remaining life, prosecution history and litigation exposure for each asset. | In: IP asset inventory, prosecution files. Out: Patent-strength assessment. |
| Valuation methodology selection | Choosing an income-, market- or cost-based valuation approach suited to the asset class and the transaction context. | In: Patent-strength assessment. Out: Selected valuation methodology. |
| Royalty-rate benchmarking | Comparing the asset against comparable licensing deals and royalty-rate data to ground the valuation in market evidence. | In: Selected valuation methodology, deal-comparable data. Out: Benchmarked royalty range. |
| Monetary value determination | Producing a defensible monetary valuation figure or range for the patent or portfolio. | In: Benchmarked royalty range. Out: Valuation figure/range. |
| Valuation report delivery | Delivering the finished valuation report to support the client’s licensing negotiation, M&A process or litigation. | In: Valuation figure/range. Out: Delivered valuation report. |
Cross-cutting technologies of the sector:
- Patent-valuation methodologies: income-, market- and cost-based approaches adapted to the specific characteristics of a biotech or pharmaceutical patent estate.
- Royalty-rate benchmarking databases: structured datasets of comparable licensing deals used to ground a valuation in observed market royalty rates.
- IP-portfolio analytics: software analyzing prosecution history, litigation exposure, claims and citations to assess a patent portfolio’s monetization readiness.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 6 steps
- 1Patent portfolio identificationThe valuation firm catalogues the patents, applications and other intangible assets that make up the biotech company’s IP estate.
- 2Prior-art and claims analysisTesting & analyticsAnalysts assess patent strength, remaining life, prosecution history and litigation exposure for each asset in the portfolio.Who can do this step matched automaticallyEsco Aster Singapore✓ ISO 9001 5,000 L industrial scale“Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”Turion Labs Singapore“Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”BRAIN Biotech Germany✓ ISO 9001 industrial scale“As a contract research organization (CRO), we provide smart, rapid, and effective solutions using cutting-edge technologies to drive customer success.”industrial scale“ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
- 3Valuation methodology selectionAn income-, market- or cost-based valuation approach is selected to fit the specific asset class and the transaction context (licensing, M&A, litigation, capital raise).
- 4Royalty-rate benchmarkingThe asset is compared against comparable licensing deals and royalty-rate data to ground the valuation in observed market evidence rather than pure theory.
- 5Monetary value determinationThe methodology and benchmark data are combined to produce a defensible monetary valuation figure or range for the patent or portfolio.
- 6Valuation report deliveryThe finished valuation report is delivered to support the client’s licensing negotiation, M&A process, capital raise or litigation.
4 · Who delivers
Matched suppliers (matched automatically)
| Tsingke Biotechnology | China | Producer | active |
| Codexis | United States | Producer | active |
| BBCA Group 丰原集团 | China | Producer | active |
| Insilico Medicine | Cayman Islands | Producer | active |
| GranBio | Brazil | Producer | active |
| Life3 Biotech | Singapore | Producer | active |
| Huazhi Rice Gene Technology | China | Services / consulting | active |
| United Therapeutics | United States | Producer | active |
| Roche Holding | Switzerland | Producer | active |
In the services and supply catalogue 1 · paid service
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Ocean Tomo | 🇺🇸 USA | Engagement-based IP valuation | Biotech startup capital-raise support | commercial |
| Consor IP Consulting | 🇺🇸 USA | AI-assisted patent valuation | Data-driven valuation methodology | commercial |
| Charles River Associates IP | 🇺🇸 USA | Economic/IP litigation valuation | Life-sciences disputes practice | commercial |
| EverEdge Global | 🇳🇿 New Zealand | Ten-asset-class valuation models | Pharma/biotech IP asset coverage | commercial |
| GreyB | 🇮🇳 India | IP Compass portfolio analytics | SEP readiness, litigation exposure analysis | commercial |
| Inngot | 🇬🇧 United Kingdom | Intangible-asset valuation toolkit | Sized for smaller biotech clients | commercial |
5 · Rules & route to market
United States
The United States hosts the largest concentration of biotech IP-valuation consultancies and royalty-rate data providers, several built on decades of patent-litigation and licensing-deal history.
Ocean Tomo’s engagement-based startup valuations, Consor’s AI-assisted methodology, CRA’s life-sciences litigation valuation#
- Ocean Tomo: runs engagement-based IP valuations for biotechnology startups, including capital-raise support for companies holding therapeutic and diagnostic patent portfolios.
- Consor IP Consulting: applies AI-assisted methods to patent valuation, treating patents as strategic business assets in a data-driven valuation practice.
- Charles River Associates (CRA): brings economic-valuation expertise to life-sciences disputes, including the distinctly biotech problem of valuing a product that may never reach market approval.
European Union
Europe and adjacent jurisdictions host specialist IP-valuation and intangible-asset consultancies serving smaller biotech and life-sciences clients alongside larger transactions.
EverEdge’s ten-asset-class valuation models, GreyB’s portfolio analytics, Inngot’s intangible-asset toolkit#
- EverEdge Global: headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios.
- GreyB: provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — including standard-essential-patent readiness reporting for licensing teams.
- Inngot: a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets, sized for smaller biotech and life-sciences companies.
China
China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese biotech IP-valuation firms searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Chinese biotech companies pursuing cross-border licensing or M&A typically engage the global valuation firms listed here, or domestic state-linked asset-appraisal institutions whose specific biotech-IP practices could not be confirmed in this screen.
Cross-border biotech IP valuation served by global consultancies#
- Cross-border engagement pattern: Chinese biotech companies pursuing licensing deals or M&A with Western partners typically retain the global valuation firms listed in this article rather than a distinct domestic biotech-IP specialist.
- Domestic gap: no Chinese-headquartered biotech IP-valuation firm confirmed by a live 2026 source was found during this screen.
6 · Money: tenders & grants
| Grant | Additional activities for the European Partnership of Agriculture of Data European Commission · EU | Nov 26, 2026 3 days |
| Grant | Biotechnology application for CCU European Commission · EU | Sep 22, 2027 303 days |
| Grant | Developing novel recycling technologies for complex plastic materials applying biotech solutions European Commission · EU | Sep 22, 2027 303 days |
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 141 days |
| Grant | Enhancing farmer's profitability and resilience through innovations for diversified crops and value chains European Commission · EU | Sep 23, 2027 304 days |
7 · Tech stack & innovations
The biotech IP-valuation technology stack combines established valuation methodology with AI-assisted analytics and structured royalty-benchmarking data:
- Patent-valuation methodologies:
- Firms such as Ocean Tomo and Charles River Associates apply income-, market- and cost-based approaches adapted to biotech-specific circumstances, including products that have not yet reached regulatory approval.
- AI-assisted valuation and portfolio analytics:
- Consor IP Consulting applies AI-assisted methods to patent valuation; GreyB’s IP Compass reviews prosecution history, litigation, claims and citations to assess monetization readiness.
- Royalty-rate benchmarking:
- ktMINE maintains royalty-rate range data drawn from thousands of biopharma licensing deals, grounding valuations in observed market transactions.
Sources 10 · 0 independent · 10 producer sites
Producers' own sites 10
- Ocean tomo producer checked 2026-07-09 · link not kept
- Consor IP consulting producer checked 2026-08-08 · link not kept
- Cra IP valuation producer checked 2026-08-04 · link not kept
- Everedge global producer checked 2026-08-11 · link not kept
- Aon IP solutions producer checked 2026-08-05 · link not kept
- Greyb producer checked 2026-07-16 · link not kept
- Ktmine producer checked 2026-08-12 · link not kept
- Zhongjinhao asset appraisal producer checked 2026-08-16 · link not kept
- Inngot producer checked 2026-05-26 · link not kept
- China sciences exchange IP producer checked 2026-08-16 · link not kept